atheroflux.eu
ATHERO-FLUXTargeting novel lipid pathways for treatment of cardiovascular disease
http://www.atheroflux.eu/
Targeting novel lipid pathways for treatment of cardiovascular disease
http://www.atheroflux.eu/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Thursday
LOAD TIME
1 seconds
PAGES IN
THIS WEBSITE
7
SSL
EXTERNAL LINKS
16
SITE IP
217.73.236.232
LOAD TIME
0.953 sec
SCORE
6.2
ATHERO-FLUX | atheroflux.eu Reviews
https://atheroflux.eu
Targeting novel lipid pathways for treatment of cardiovascular disease
atheroflux.eu
ATHERO-FLUX
http://www.atheroflux.eu/objectives.html
Athero-Flux aims to identify, characterise and validate novel therapeutic targets for CVD by dissecting the biosynthesis and pro-atherogenic potential of specific molecular species of SLs identified by lipidomics as strong predictors of CV risk in large-scale clinical studies. To identify the steps regulating the generation and signalling of specific SLs. Relevant to CV risk. To validate therapeutic targets in SL metabolism and downstream signalling. To develop clinically applicable LNA.
ATHERO-FLUX
http://www.atheroflux.eu/project.html
CVD causes much of the disease burden in Europe, claiming each year 4.3 million lives in Europe, 2.0 million in the EU (. European Heart Network; www.ehnheart.org. The main forms of CVD are coronary artery disease. CAD by itself is the single most common cause of death in Europe: accounting for 1.8 million deaths in Europe and 681,000 deaths in the EU per year (. European Heart Network;. Builds on the lipidomics findings that a class of lipids ( SLs. Have revealed that specific sphingolipids (SLs). Of th...
ATHERO-FLUX
http://www.atheroflux.eu/structure.html
Workflow enables close integration between the Academic and SME capacities. The planned Academic and SME partnership will feed potential targets into the SME pipeline. The Academia will provide knowledge and experience in SL biology and state-of-the-art. Models of atherosclerosis. The SMEs will in turn offer high-throughput lipidomics and screening technologies as well as LNA validation tools with a proven translational pipeline. WP1 and WP2 form the TARGET IDENTIFICATION PHASE. The effect of systemic fa...
ATHERO-FLUX
http://www.atheroflux.eu/participants.html
Participant short and full name. The Chancellor, Masters and Scholars of the University of Oxford. TERMINATED February 28th, 2015. Roche Innovation Center Copenhagen A/S. Marie Wickström Lindholm. Biomedical Research Foundation Academy of Athens. Katriina Aalto-Setälä. Philippe J. Sansonetti. Göran K. Hansson. Weizmann Institute of Science. ALTA Ricerca e Sviluppo. In Biotecnologie S.r.l.u. From March 1st, 2015).
ATHERO-FLUX
http://www.atheroflux.eu/meetings.html
Next Annual meeting, Asnières-sur-Oise, 7-8 November 2016. Annual meeting, Athens, 3-4 November 2015. Annual meeting, Siena, 21-23 September 2014. Download the agenda (Joint Meeting). Kick-off meeting, Oxford, 01-03 October 2013.
TOTAL PAGES IN THIS WEBSITE
7
ALTA
http://www.altaweb.it/mission.html
Role and main tasks of ALTA. Why fund raising is necessary? 2010 ALTA S.r.l.u. - Via Fiorentina, 151 - 53100 Siena - Italy. Tel 39 0577 50518 fax 39 0577 593815. Capitale sociale € 10.845,00. CF 12364330154 P.IVA 01033520527.
ALTA
http://www.altaweb.it/people.html
Maria Grazia De Leon. Communication and Events Manager. 2010 ALTA S.r.l.u. - Via Fiorentina, 151 - 53100 Siena - Italy. Tel 39 0577 50518 fax 39 0577 593815. Capitale sociale € 10.845,00. CF 12364330154 P.IVA 01033520527.
ALTA
http://www.altaweb.it/news_archive.html
PROJECTS APPROVED IN THE 2015 CALL - HORIZON 2020. Health, demographic change and wellbeing:. Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of comorbidities. PROJECTS APPROVED IN THE 2015 CALL - HORIZON 2020. Innovative Training Networks (ITN) European Training Networks (ETN):. A training network for the rational design of the next generation of well-defined glycoconjugate vaccines. Probing safety of nano-objects by defining immune responses of environmental organisms. The First ...
ALTA
http://www.altaweb.it/projects.html
Founded in 1998, ALTA is now managing several international projects. In particular, ALTA is involved in research projects of the European Commission in the field of biomedicine and biotechnology. Framework Program, ALTA is directly involved in EU-funded projects as participant for management activities. 18 research projects awarded. Project value € 118.185.078. 17 PEOPLE projects awarded. Project value 19.161.055. 9 research projects awarded. Project value 70.034.208. 7 research projects awarded.
ALTA
http://www.altaweb.it/index.html
Is a service-provider company specialized in developing and managing scientific research projects. The mission of ALTA is to support research activities from the idea to the realization of project. ALTA assists in finding the proper strategy, building European Consortia and putting science in the most appropriate administrative and management framework. PROJECTS APPROVED IN THE 2016-2017 CALL - HORIZON 2020. Climate action, environment, resource efficiency and raw materials. And impact of comorbidities.
ALTA
http://www.altaweb.it/pictures.html
ALTA staff and offices. Princess Anne at the exhibition Hands for Life, Hands for Hope. 25 september 2008 - St. George's - University of London. Complesso Museale S. Maria della Scala - Siena. Mostra fotografica (5 novembre - 13 gennaio 2010). EIMID Meeting - Arc et Senans, France - (October 2008). ALTA celebrates 10 years of activity. 2010 ALTA S.r.l.u. - Via Fiorentina, 151 - 53100 Siena - Italy. Tel 39 0577 50518 fax 39 0577 593815. Capitale sociale € 10.845,00. CF 12364330154 P.IVA 01033520527.
ALTA
http://www.altaweb.it/old_projects.html
Fungi in the setting of inflammation, allergy and autoimmune diseases: Translating basic science into clinical practices. European Institute of Microbiology and Infectious Diseases. Set up and comparison of multiple stem cell approaches for kidney repair. Design of a vaccine to immunize neonates against GBS infections through a durable maternal immune response. European Vaccines and Microbicides Enterprise. New preventative and therapeutic Hepatitis C vaccines: from pre-clinical to phase 1. New carbohydr...
ALTA
http://www.altaweb.eu/news_archive.html
PROJECTS APPROVED IN THE 2015 CALL - HORIZON 2020. Health, demographic change and wellbeing:. Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of comorbidities. PROJECTS APPROVED IN THE 2015 CALL - HORIZON 2020. Innovative Training Networks (ITN) European Training Networks (ETN):. A training network for the rational design of the next generation of well-defined glycoconjugate vaccines. Probing safety of nano-objects by defining immune responses of environmental organisms. The First ...
TOTAL LINKS TO THIS WEBSITE
16
ATHERO-B-CELL
Targeting and exploiting B cell. Functions for treatment in. The treatment of risk factors, albeit beneficial, has reached its full potential in CVD and new treatments should be targeted to novel disease factors. Inflammation is the important component of the pathogenesis of CVD that is not yet therapeutically targeted. B cells are a classic example of the contrasting role of immune cell subsets in CVD. Harnessing protective or abating unwanted B cell responses has the potential to shed light on the path...
Blog de atherock - Athé... - Skyrock.com
Mot de passe :. J'ai oublié mon mot de passe. Plus d'actions ▼. S'abonner à mon blog. Création : 07/08/2009 à 17:29. Mise à jour : 13/07/2011 à 16:10. Ben pas besoin . Si tu vois vraiment qui je suis ben t'as tout compris :). Si pas ben tampis et part. Un jour on aime, un jour on trahi ou on est trahi, un jour on pardonne, un jour on est mal, un jour on veut mourir, un jour on est heureux, un jour on se sent mieux, mais quand on est mal de vrais amis sont là pour nous! Ou poster avec :. Retape dans le ch...
Renal Remission & Hypertension Clinic
Coming Soon - Future home of something quite cool
Future home of something quite cool. If you're the site owner. To launch this site. If you are a visitor. Please check back soon.
お医者さんのサプリメント（ＥＰＡ、ＤＨＡ、発酵穀類、プロポリス） | お医者さんが考案したアテロカットは、動脈硬化の予防に推奨されているEPA，DHAに天然の抗生物質といわれるプロポリスやビタミンの豊富な大豆・玄米・鳩麦を発酵させて作り出した多種類の酵素および、緑茶や小麦胚芽などを加えた栄養補助食品です。
EPA、DHAってなに それは、一言でいうと お魚の脂 のことです。
ATHERO-FLUX
Lipid lowering has significantly reduced cardiovascular disease. CVD) mortality in EU. However, the aim to abolish CVD in EU is far from achieved and attempts to improve on the benefits of statins with new agents have not yet delivered new therapeutics. The Consortium Athero-Flux. Builds on FP7-generated large-scale lipidomics data. Showing that specific sphingolipids (SLs). A better primary and secondary prevention of CVD events than with statins alone can be achieved. 21-23 September, Siena. The Chance...
Price Request - BuyDomains
Url=' escape(document.location.href) , 'Chat367233609785093432', 'toolbar=0,scrollbars=0,location=0,statusbar=0,menubar=0,resizable=0,width=640,height=500');return false;". Need a price instantly? Just give us a call. Toll Free in the U.S. We can give you the price over the phone, help you with the purchase process, and answer any questions. Get a price in less than 24 hours. Fill out the form below. One of our domain experts will have a price to you within 24 business hours. United States of America.
@HEROgenics – Informations about your Health
Many people take heart health for granted. They assume that as long as they are feeling good or are not over weight that their heart must be in good shape. Heart disease and the risk of potencypills. There are several men who are experiencing erectile dysfunction problems in various forms such as penis erectile dysfunction during sexual intercourse, or experiencing shorter time on erection. How Antioxidants Could Help to Reduce Heart Attacks and Strokes.
www.atherogenomics – www.atherogenomics.de
In kürze ist Inhalt für www.atherogenomics.de verfügbar. 16 Mar 2018 - 19:32. Wwwatherogenomics.de wird bald hier erscheinen.
KODG58G5166 - keepalive.aspx
KODG58G5166 - www.atheroinfo.com. Cache-Control: no-store,no-cache Connection: Keep-Alive Pragma: no-cache Content-Type: application/x-www-form-urlencoded Accept: text/html, application/xaml xml, */* Accept-Encoding: gzip, deflate Accept-Language: en-us Host: www.atheroinfo.com Referer: http:/ www.pageglimpse.com/atheroinfo.com User-Agent: Mozilla/5.0 (compatible; Googlebot/2.1; http:/ www.google.com/bot.html) CLIENT-IP: 173.164.136.238. C: inetpub wwwroot keepalive.aspx.
KODG58G5166 - keepalive.aspx
KODG58G5166 - www.atheroinformation.com. HTTP CACHE CONTROL:no-store,no-cache HTTP CONNECTION:Keep-Alive HTTP PRAGMA:no-cache HTTP CONTENT TYPE:application/x-www-form-urlencoded HTTP ACCEPT:text/html, application/xaml xml, */* HTTP ACCEPT ENCODING:gzip, deflate HTTP ACCEPT LANGUAGE:en-us HTTP HOST:www.atheroinformation.com HTTP REFERER:http:/ www.pageglimpse.com/atheroinformation.com HTTP USER AGENT:Mozilla/5.0 (compatible; Googlebot/2.1; http:/ www.google.com/bot....C: inetpub wwwroot keepalive.aspx.
